Skip to content
MondayNightIBD
Evolving Treatment Targets and Monitoring Strategies in Crohn's Disease
October 14, 2024 ~ Jami Kinnucan, MD
**Pre-assessment**
Before you view this activity, please take this pre-assessment.
Taking this pre-assessment does not immediately qualify learners to earn credit.
Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
*
1.
What are your specialty and credentials?
(Required.)
IBD Specialist
General GI
Colorectal Surgeon
Fellow/Trainee
APP
Nurse
PharmD
Other (please specify)
2.
What is your community of practice?
Academic
Community
Industry
*
3.
According to STRIDE-II, which of the following is considered an intermediate treatment target for IBD?
(Required.)
Endoscopic healing
Normalization of CRP
Normalization of quality of life
Symptomatic improvement
*
4.
A 32-year-old woman with newly diagnosed Crohn’s ileocolitis is started on ustekinumab and achieves endoscopic healing at year 1 with some pseudopolyps in right colon and a short non-obstructing fibrotic stenosis at the ileocaecal valve.
Which of following is a long term T2T for her?
(Required.)
Prevent disability
Reverse fibrosis
Treat the pseudopolyps
Be able to stop therapy
5.
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.
First & Last Name, Credentials
🔗
Proceed to activity on X/MondayNightIBD
🔗
Proceed to post-survey
(post-survey completion must occur on or after activity launch date to be valid for claiming credit)
